MX2024003248A - Compuestos moduladores de gpr52. - Google Patents

Compuestos moduladores de gpr52.

Info

Publication number
MX2024003248A
MX2024003248A MX2024003248A MX2024003248A MX2024003248A MX 2024003248 A MX2024003248 A MX 2024003248A MX 2024003248 A MX2024003248 A MX 2024003248A MX 2024003248 A MX2024003248 A MX 2024003248A MX 2024003248 A MX2024003248 A MX 2024003248A
Authority
MX
Mexico
Prior art keywords
sup
gpr52
modulating compounds
ameliorating
disclosures
Prior art date
Application number
MX2024003248A
Other languages
English (en)
Spanish (es)
Inventor
Michael Alistair O'brien
Nigel Alan Swain
Stephen Paul Watson
Original Assignee
Nxera Pharma Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nxera Pharma Uk Ltd filed Critical Nxera Pharma Uk Ltd
Publication of MX2024003248A publication Critical patent/MX2024003248A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/661Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2024003248A 2021-09-15 2022-09-15 Compuestos moduladores de gpr52. MX2024003248A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB2113186.7A GB202113186D0 (en) 2021-09-15 2021-09-15 GPR52 Modulator compounds
PCT/GB2022/052328 WO2023041909A1 (en) 2021-09-15 2022-09-15 Gpr52 modulator compounds

Publications (1)

Publication Number Publication Date
MX2024003248A true MX2024003248A (es) 2024-04-02

Family

ID=78149263

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024003248A MX2024003248A (es) 2021-09-15 2022-09-15 Compuestos moduladores de gpr52.

Country Status (22)

Country Link
US (1) US20240376070A1 (https=)
EP (1) EP4401833B1 (https=)
JP (1) JP2024535860A (https=)
KR (1) KR20240058852A (https=)
CN (1) CN117999258A (https=)
AU (1) AU2022348201A1 (https=)
CA (1) CA3232606A1 (https=)
CL (1) CL2024000742A1 (https=)
DK (1) DK4401833T3 (https=)
ES (1) ES3053759T3 (https=)
FI (1) FI4401833T3 (https=)
GB (1) GB202113186D0 (https=)
HR (1) HRP20251420T1 (https=)
IL (1) IL311015A (https=)
LT (1) LT4401833T (https=)
MX (1) MX2024003248A (https=)
PL (1) PL4401833T3 (https=)
PT (1) PT4401833T (https=)
RS (1) RS67399B1 (https=)
SI (1) SI4401833T1 (https=)
SM (1) SMT202500449T1 (https=)
WO (1) WO2023041909A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202206413A (zh) 2020-04-22 2022-02-16 美商紐羅克里生物科學有限公司 Gpr52調節劑及其使用方法
WO2025252061A1 (zh) * 2024-06-04 2025-12-11 海思科医药集团股份有限公司 一种gpr52激动剂及其在医药上的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180004193A (ko) 2015-04-29 2018-01-10 아레나 파마슈티칼스, 인크. Gpr52와 관련된 장애의 치료 또는 예방을 위한 gpr52 조절제로서 1-헤테로아릴-인돌린-4-카르복스아미드
JP7394747B2 (ja) * 2017-09-13 2023-12-08 ノバルティス アーゲー ジフェニル誘導体及びその使用
CA3156474A1 (en) * 2019-11-08 2021-05-14 Heptares Therapeutics Limited GPR52 MODULATING COMPOUNDS
GB202003668D0 (en) 2020-03-13 2020-04-29 Heptares Therapeutics Ltd GPR52 Modulator compounds

Also Published As

Publication number Publication date
AU2022348201A1 (en) 2024-03-28
KR20240058852A (ko) 2024-05-07
EP4401833A1 (en) 2024-07-24
LT4401833T (lt) 2025-12-10
WO2023041909A1 (en) 2023-03-23
GB202113186D0 (en) 2021-10-27
JP2024535860A (ja) 2024-10-02
FI4401833T3 (fi) 2025-11-25
SI4401833T1 (sl) 2026-01-30
EP4401833B1 (en) 2025-10-22
DK4401833T3 (da) 2025-11-17
PT4401833T (pt) 2025-11-14
CN117999258A (zh) 2024-05-07
PL4401833T3 (pl) 2026-02-16
HRP20251420T1 (hr) 2026-01-02
RS67399B1 (sr) 2025-11-28
ES3053759T3 (en) 2026-01-26
CL2024000742A1 (es) 2024-09-27
IL311015A (en) 2024-04-01
US20240376070A1 (en) 2024-11-14
SMT202500449T1 (it) 2026-01-12
CA3232606A1 (en) 2023-03-23

Similar Documents

Publication Publication Date Title
MX2022005111A (es) Compuestos moduladores del receptor 52 acoplado a proteina g (gpr52).
CR20200373A (es) Compuestos
MX2022011333A (es) Compuestos moduladores de gpr52.
MX2021004280A (es) Derivados de pirazol como compuestos antagonistas de receptor de histamina h4.
MX2022009369A (es) Compuestos y usos de estos.
MX381588B (es) N-(fenilsulfonil)benzamidas y compuestos relacionados como inhibidores de bcl-2.
MY208662A (en) Modulators of methyl modifying enzymes, compositions and uses thereof
MX2024003248A (es) Compuestos moduladores de gpr52.
PE20260502A1 (es) Fluoroalquil-oxadiazoles y usos de los mismos
MX2021011753A (es) Degradadores de moleculas peque?as de stat3.
MX2025009912A (es) Compuestos moduladores de mc2r
MX2022000812A (es) Metodos de tratamiento de hiperplasia suprarrenal congenita.
MX2020002824A (es) Aminas beta-hidroxi heterociclicas y su uso en el tratamiento de la hiperglucemia.
EA202191519A1 (ru) Модуляторы trex1
WO2021079196A3 (en) Mettl3 modulators
JO3571B1 (ar) كحولات ثلاثي فلوروميثيل كمُعدلات للمستقبل النووي جاما تي المرتبط بحمض الريتيونَويك ror-gamma-t
MX2020009443A (es) Método de modulación de las vías de señalización de tigit y pd-1 mediante el uso de compuestos de 1,2,4-oxadiazol.
CR20130055A (es) Compuestos aromáticos apropiados para tratar trastornos que responden a la modulación del receptor de dopamina d3
MX2022000811A (es) Inhibidores de enzimas.
AR020660A1 (es) Composiciones antibioticas para el tratamiento de ojos, oidos y nariz
MX2024012874A (es) Antagonistas ccr4
PH12019501566A1 (en) Amide compounds and use thereof
BR112023003696A2 (pt) Compostos moduladores de gpr52
MX2022000165A (es) Moduladores del receptor alfa relacionado con estrogeno (err alfa ).
WO2020074927A3 (en) Glp-1 receptor antagonists